All news

FMBA plans to manufacture up to 30 million Convacell doses every year

The medicine is to be manufactured by production facilities of the new recombinant vaccine workshop

MOSCOW, March 19. /TASS/. The production facility of the St. Petersburg Research Institute of Vaccines and Serums under the Federal Medical-Biological Agency (FMBA) plans to produce up to 30 million of Convacell vaccine sets every year, the agency’s press service said on Saturday.

"The medicine is to be manufactured by production facilities of the new recombinant vaccine workshop, opened on the basis of the St. Petersburg Research Institute of Vaccines and Serums under the Federal Medical-Biological Agency (FMBA) in 2021, as part of the Year of Science and Technologies in Russia. The production facility has the capacity of manufacturing up to 30 million double doses annually," the statement says.

FMBA chief Veronika Skvortsova said earlier that the vaccine is unlikely to cause any allergic reaction and is well tolerated by patients.

On Friday, the Russian health ministry has registered the Convacell anti-coronavirus vaccine, developed by the St. Petersburg Research Institute of Vaccines and Serums under the Federal Medical-Biological Agency (FMBA) of Russia.

In June 2021, preclinical studies of the vaccine were completed, proving its safety, immunogenicity and protective potential.